I would like to comment on an interesting article by Kessing et al. entitled 'New drug candidates for depression - a nationwide population-based study'(1). It presents a long-term study aimed to screen the Danish population register for the possible association between the exposure to certain clinically approved drugs: such as statins, high-dose aspirin and non aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), which possess anti-inflammatory or neuroprotective properties, and the rate of incident depression. Although there has been increasing evidence that suppressing the ongoing inflammatory process could facilitate the response of patients with refractory depression to standard antidepressant drugs (2), Kessing et al. This article is protected by copyright. All rights reserved.

中文翻译：

---

评论“抑郁症的新候选药物——一项全国性的人群研究”

我想评论 Kessing 等人的一篇有趣的文章。题为“抑郁症的新候选药物——一项全国性的基于人群的研究”(1)。它提出了一项长期研究，旨在筛查丹麦人口登记册中某些临床批准药物暴露之间可能存在的关联：例如他汀类药物、高剂量阿司匹林和非阿司匹林非甾体抗炎药 (NSAID)，它们具有抗-炎症或神经保护特性，以及抑郁症的发生率。尽管越来越多的证据表明抑制持续的炎症过程可以促进难治性抑郁症患者对标准抗抑郁药的反应 (2)，但 Kessing 等人。本文受版权保护。版权所有。